NIHON CHOUZAI Co.,Ltd. (3341.T)
- Previous Close
3,040.00 - Open
3,025.00 - Bid 3,140.00 x --
- Ask 3,150.00 x --
- Day's Range
3,020.00 - 3,165.00 - 52 Week Range
1,098.00 - 3,365.00 - Volume
161,800 - Avg. Volume
309,550 - Market Cap (intraday)
93.958B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
67.62 - EPS (TTM)
46.51 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield 25.00 (0.82%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
1,480.00
NIHON CHOUZAI Co.,Ltd. engages in the management of health insurance dispensing chain pharmacies in Japan. It operates through dispensing pharmacy, pharmaceutical manufacturing and sales, and medical staff dispatching and referral business segments. The company manufactures and sells generic drugs to medical institutions and other pharmacies. In addition, it offers temporary staffing services for pharmacist; and employment services for physicians and registered sales personnel, and other healthcare professionals. Further, the company provides studies and research services for pharmaceutical companies and organizations; information and consulting services for industries associated with pharmaceuticals and healthcare; and other services. NIHON CHOUZAI Co.,Ltd. was incorporated in 1980 and is headquartered in Tokyo, Japan.
www.nicho.co.jp--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: 3341.T
更多內容Performance Overview: 3341.T
Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
比較: 3341.T
選擇以關鍵表現數據分析類似公司；最多可選擇 4 個股份。
Statistics: 3341.T
更多內容Valuation Measures
Market Cap
90.82B
Enterprise Value
121.63B
Trailing P/E
65.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.25
Price/Book (mrq)
1.54
Enterprise Value/Revenue
0.34
Enterprise Value/EBITDA
9.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.39%
Return on Assets (ttm)
1.78%
Return on Equity (ttm)
2.37%
Revenue (ttm)
360.51B
Net Income Avi to Common (ttm)
1.39B
Diluted EPS (ttm)
46.51
Balance Sheet and Cash Flow
Total Cash (mrq)
27.46B
Total Debt/Equity (mrq)
98.60%
Levered Free Cash Flow (ttm)
-3.73B